3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Small Cell Lung Carcinoma
2
Neoplasms
2
Head and Neck Neoplasms
2
Gastrointestinal Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Merkel Cell
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Turcot syndrome
1
Stomach Neoplasms
1
Sarcoma
1
Penile Neoplasms
1
PD-L1 Positive Mutation Tumor
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Melanoma
1
Lymphoma, Extranodal NK-T-Cell
1
Leukemia, Myeloid, Chronic-Phase
1
Hodgkin Disease
1
Hemangiosarcoma
1
Glioblastoma
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Interventions
Cyclophosphamide
12
Etoposide
10
Doxorubicin
9
Brentuximab Vedotin
8
fludarabine phosphate
7
Vinblastine
7
Dacarbazine
7
Bleomycin
7
Vincristine
6
Melphalan
6
camrelizumab
5
Radiotherapy
5
Nivolumab
5
Mycophenolic Acid
5
Decitabine
5
pembrolizumab
4
Rituximab
4
Peripheral Blood Stem Cell Transplantation
4
Gemcitabine
4
Filgrastim
4
Cytarabine
4
Cyclosporine
4
Busulfan
4
Bendamustine Hydrochloride
4
ABVD protocol
4
Tacrolimus
3
Prednisone
3
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
3
Ifosfamide
3
Carboplatin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Hodgkin Disease
×
avelumab
×
Clear all
NCT03617666
2023-12-12
AVENuE
University College, London
Phase 2
Unknown
49 enrolled